Sign In
Buy GERN
$1.16
-0.0100 (-0.85%)
At Close: Jun 03, 2026
Geron Plans to Announce Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026
07:27am, Wednesday, 11'th Feb 2026
FOSTER CITY, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, tod
CG Oncology (NASDAQ:CGON) and Geron (NASDAQ:GERN) Head-To-Head Comparison
01:46am, Tuesday, 10'th Feb 2026
Geron (NASDAQ: GERN - Get Free Report) and CG Oncology (NASDAQ: CGON - Get Free Report) are both medical companies, but which is the superior investment? We will compare the two businesses based on th
Geron: Underpromise And Overdeliver Could Be The 2026 Strategy (Rating Upgrade)
11:58pm, Tuesday, 27'th Jan 2026
Geron's new CEO has positioned Rytelo as a 2026 growth story, following a lack of sales growth in 2025. GERN announced a restructuring in December and gave some financial guidance in January, includin
Geron Corporation Provides 2026 Financial Guidance
08:00am, Monday, 12'th Jan 2026
2026 RYTELO ® (imetelstat) net product revenue expected in the range of $220 to $240 million 2026 total operating expenses expected in the range of $230 to $240 million Expected top-line growth and s
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Thursday, 18'th Dec 2025
FOSTER CITY, Calif., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that, effective December 17, 2025, it granted stoc
Geron Corporation Announces Strategic Restructuring Plan to Position the Company for Long-Term Value Creation
08:00am, Thursday, 11'th Dec 2025
Restructuring Supports RYTELO® U.S. Commercial Strategy and Investment in Clinical Development Expected to Reduce 2026 Projected Operating Expenses FOSTER CITY, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE)
Oral presentation from pooled analyses of the IMerge population suggests that treatment-emergent cytopenias may reflect on-target effects associated with meaningful clinical outcomes, including hemogl
Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points
12:20pm, Thursday, 04'th Dec 2025
/PRNewswire/ -- Triple-therapy immunotherapy approaches are demonstrating complete leukemia elimination in preclinical models by reprogramming how cancer cells
Stock Traders Purchase Large Volume of Put Options on Geron (NASDAQ:GERN)
02:19am, Saturday, 15'th Nov 2025
Geron Corporation (NASDAQ: GERN - Get Free Report) was the target of some unusual options trading activity on Friday. Stock investors purchased 4,000 put options on the stock. This represents an incre
Geron: Rytelo Launch Stalls Out, EU Partnership And IMpactMF Results Could Help
08:15am, Friday, 07'th Nov 2025
Geron reported Q3'25 Rytelo revenues of $47.2M, down from $49M in Q2, with no underlying increase in demand reported. Despite efforts to boost Rytelo's use in first and second-line therapy (now 36%, u
Geron Corporation (GERN) Q3 2025 Earnings Call Transcript
02:21pm, Wednesday, 05'th Nov 2025
Geron Corporation ( GERN ) Q3 2025 Earnings Call November 5, 2025 8:00 AM EST Company Participants Dawn Schottlandt - Senior Vice President of Investor Relations & Corporate Affairs Harout Semerjian -
Geron (GERN) Reports Q3 Loss, Lags Revenue Estimates
09:26am, Wednesday, 05'th Nov 2025
Geron (GERN) came out with a quarterly loss of $0.03 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.04 per share a year ago.
Geron Corporation Reports Third Quarter 2025 Financial Results and Recent Business Highlights
07:00am, Wednesday, 05'th Nov 2025
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today reported finan
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that
Geron (GERN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
11:08am, Wednesday, 29'th Oct 2025
Geron (GERN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
